Leukemic blasts from patients with acute phase chronic myeloid leukemic and refractory acute myeloid leukemia are highly resistant to a number of cytotoxic drugs. To overcome multi-drug resistance, we engineered a diphtheria fusion protein by fusing human interleukin-3 (IL3) to a truncated form of diphtheria toxin (DT) with a (G 4 S) 2 linker (L), expressed and purified the recombinant protein, and tested the cytotoxicity of the DTLIL3 molecule on human leukemias and normal progenitors. The DTLIL3 construct was more cytotoxic to interleukin-3 receptor (IL3R) bearing human myeloid leukemia cell lines than receptor-negative cell lines based on assays of cytotoxicity using thymidine incorporation, growth in semi-solid medium and induction of apoptosis. Exposure of mononuclear cells to 680 pM DTLIL3 for 48 h in culture reduced the number of cells capable of forming colonies in semi-solid medium (colony-forming units leukemia) у10-fold in 4/11 (36%) patients with myeloid acute phase chronic myeloid leukemia (CML) and 3/9 (33%) patients with acute myeloid leukemia (AML). Normal myeloid progenitors (colony-forming unit granulocytemacrophage) from five different donors treated and assayed under identical conditions showed intermediate sensitivity with three-to five-fold reductions in colonies. The sensitivity to DTLIL3 of leukemic progenitors from a number of acute phase CML patients suggests that this agent could have therapeutic potential for some patients with this disease. Leukemia (2000) 14, 576-585.
Introduction
Both the natural history of acute phase CML and relapsed or refractory AML is characterized by short survival (median of around 6 months) and resistance to cytotoxic chemotherapy.
1,2 Chemotherapy-resistant blasts are a frequent cause of treatment failure in these patients. 3 In many cases, the blasts exhibit a multi-drug resistance phenotype. New reagents with unique mechanisms of action that can selectively modify the apoptotic threshold of malignant blasts are needed.
One such class of leukemia therapeutics is targeted toxin molecules. These drugs consist of myeloid leukemia-directed ligands covalently linked to protein synthesis inactivating peptide toxins. We previously selected human granulocytemacrophage colony-stimulating factor (GM-CSF) as the ligand and fused the peptide to a truncated form of diphtheria toxin (DT) containing amino acids 1-388 of DT to produce a fusion protein, DTGM. 4 DTGM reduced leukemic progenitor colony formation у1 log in 85% of AML patients, 71% of juvenile myelomonocytic leukemia (JMML) patients and 60% of adult chronic myelomonocytic leukemia (CMML) patients. 5, 6 We have scaled up production of DTGM under good manufacturing practice (GMP) 7 and are currently performing a phase I dose-escalation clinical study for patients with relapsed or refractory AML. However, because DTGM was ineffective against acute phase CML patient blasts and 15% of AML patient blasts, we sought an additional ligand for targeting.
Interleukin-3 (IL3) is a cytokine which supports the proliferation and terminal differentiation of multipotential and committed myeloid and lymphoid progenitors, 8 but does not act on the most primitive hematopoietic stem cells. 9 The IL3 receptor (IL3R) has been demonstrated by 125 I-labeled IL3 binding to be present on human myeloid leukemic cells. 10 Further, acute phase CML blasts proliferate in response to exogenous IL3. 11, 12 In fact, CML progenitors have been reported to overexpress both IL3 and IL3R, yielding an autocrine loop stimulation of proliferation. 13 This also occurs in certain autocrine transformed mouse leukemia cell lines. 14 The IL3R is composed of ␣ and ␤ subunits. 15 The binding of IL3 to its receptor causes rapid internalization of the ligandreceptor complex. 16 Thus, based on the expression of its receptor on blasts from patients with acute phase CML and AML and its rapid receptor-mediated endocytosis on receptor coupling, we chose to fuse IL3 to the catalytic and translocation domains of diphtheria toxin (DT).
The goal of the present study was to synthesize an IL3-diphtheria toxin fusion molecule, purify and characterize the molecule chemically, and evaluate the toxicity of the fusion protein towards leukemia cell lines and progenitors from normal individuals as well as patients with either acute phase CML or AML.
Materials and methods

Plasmid construction
Primers and the polymerase chain reaction (PCR) were used to introduce NdeI and HindIII restriction sites at the ends of the IL3 gene so that the target IL3 could then be directly ligated into a previously constructed expression vector pRKDTGM encoding both diphtheria toxin (DT) and GM-CSF (GM). The GM was released from the expression vector by enzymatic digestion with NdeI plus HindIII and the new NdeI/HindIII IL3 fragment was ligated into the construct in its place. The IL3 DNA insert with NdeI and HindIII restriction sites at the ends was synthesized by PCR from a pUC18 plasmid containing mature human IL-3 cDNA (Catalog No. BBG14, Research Diagnostics, Minneapolis, MN, USA). An IL3 DNA insert with a (Gly 4 Ser) 2 linker was prepared. Amplification was performed using the Perkin Elmer GeneAmp PCR Reagent Kit (Perkin Elmer Cetus, Norwalk, CT, USA). The 577 primer for the 5Ј end was 5Ј-GCAGTCGACCATATGG-GCGGAGGCGGAAGTGGAGGAGGAGGCAGCGCTCC-CAT GACCCAGACA-3Ј. The primer for the 3Ј end was 5Ј-GCAGTCGCAAAGC-TTCTAAAAGATCGCTAGCGACAA-3Ј. The IL3 DNA was amplified according to the manufacturer's instructions in 10 mM Tris-HCl (pH 8.3)/2.5 mM MgCl 2 /50 mM KCl reaction mixture containing 200 M of each of the four nucleotide triphosphates, 1 g/ml of each primer, and 3 units of TaqGold DNA polymerase (Perkin-Elmer Cetus). After an initial denaturation step for 5 min at 94°C, the 40 ng of pUC18-IL3 was amplified by 40 cycles of denaturation at 94°C for 1 min, annealing at 50°C for 1 min, and extension at 72°C for 1 min followed by an extended extension at 74°C for 7 min.
PCR product was then subcloned in the pCR-TOPO vector following the instructions of the manufacturer (TOPO TA Cloning, Version D, InVitrogen, Carlsbad, CA, USA). Plasmid DNA was isolated from stationary culture using the Wizard Plus SV Miniprep DNA Purification System (Promega, Madison, WI, USA) following the manufacturer's instructions and sequenced using the M13 universal forward and reverse primers to confirm correct sequence for the IL3 construct. Both the IL3 vector and the pRKDTGM plasmid 17 DNAs were digested with NdeI and HindIII. The 0.4 kb IL3 DNA fragment and 3.7 kb pRKDT DNA fragment were isolated from 0.7% low melting point GTG NuSieve agarose gels (FMC Corporation, Rockland, ME, USA) using the QiaQuick PCR Purification kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. The vector fragment was dephosphorylated with shrimp alkaline phosphatase (Boehringer Mannheim, Indianapolis, IN, USA), heat inactivated and ligated to the IL3 insert using T4 DNA ligase polymerase (Promega). A Qiagen Maxi-Prep of pRKDTLIL3 (containing a (G 4 S) 2 linker between DT388 and IL3) was prepared and the plasmid sequenced with an Applied Biosystems Prism Dye Terminator Dideoxy cycle-sequencing kit and automated sequencer (Applied Biosystems, Foster City, CA, USA). The plasmid encoded a methionine followed by the first 388 amino acid residues of diphtheria toxin followed by the HisMet and a (G 4 S) 2 linker followed by IL3.
Expression and purification of DTLIL3
Competent E. coli BLR (DE3) (Novagen, Milkwaukee, WI, USA) were transformed with 1.5 l of pRKDTLIL3 (containing the (G 4 S) 2 linker) as previously described. 7 Colonies from 20 100 mm LB ampicillin plates were pooled and added to 3 of superbroth containing 0.8 mM MgSO 4 and 0.25% dextrose and shaken in two 6 l Fernbach flasks at 37°C. When the culture reached an OD 650 of 0.6 (2.5 h), 1 mM IPTG (Sigma, St Louis, MO, USA) was added. Two hours later, the cells were harvested by centrifugation, resuspended in 480 ml TES (100 mM Tris pH 8, 1 mM EDTA, 50 mM NaCl) containing 125 mg lysozyme, homogenized with a tissuemizer (IKA Works, Wilmington, NC, USA), incubated 45 min at room temperature, and pelleted. The inclusion bodies were washed four times with TES + 2.5% Triton X-100, and four times with TES alone. The inclusion bodies were then dissolved in 12 ml of 7 M guanidine HCl/100 mM Tris pH 8/1 mM EDTA containing 120 mg dithioerythritol, homogenized and incubated 4 h at room temperature, and pelleted. The supernatant (80 mg total protein) was added dropwise to a stirring 4°C 1200 ml 0.5 M L-arginine/1 mM EDTA/0. 
Characterization of DTLIL3
Protein was quantitated by the Coomassie Plus assay as per recommendations of the supplier (Pierce, Rockford, IL, USA).
Aliquots of DTLIL3 and prestained Rainbow molecular weight standards (Amersham, Chicago, IL, USA), human IL3 (Propertech, Rocky Hill, NJ, USA) and DTGM were run on a reducing 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and either stained with Coomassie Blue R-250 (Sigma Chemical) or transferred to nitrocellulose, blocked with 10% non-fat dry milk, 0.1% sodium azide, 0. To measure the enzymatic activity of DTLIL3, the ADP ribosylation assay modified from Collier and Kandel 18 by Hwang and colleagues 19 was employed. 18, 19 Varying amounts of transferrin-CRM107 20 or DTLIL3 in 480 l DTEB buffer consisting of 0.2% BSA, 40 mM DTT, 1 mM EDTA, and 50 mM Tris pH 8.0 were mixed with 10 l 14 C-NAD (NEN-DuPont, NEC743, 588 Ci/mmol, 10 Ci/ml) and 10 l wheat germ extract (Promega, L418A). Samples were incubated at 37°C for 30 min, and protein precipitated for 15 min with 4°C 0.5 ml 12% TCA. Samples were centrifuged at 25 000 g in a microfuge, washed with 1 ml 6% TCA, and dissolved in 0.3 ml 0.1 M NaOH. Samples were then added to scintillation vials with 0.2 ml 1 N HCL. Three ml scintillation fluid was added (Ecolite, ICN), and samples were counted in a Beckman LS1800 liquid scintillation counter (Beckman Instruments, Palo Alto, CA, USA). Molarity of diphtheria fragment A containing molecules vs acid precipitable c.p.m. was plotted.
Free thiols were determined by the use of Ellman's reagent and spectrophotometry as described. 21 Two-dimensional PAGE with isoelectric focusing was carried out using pH 3.5-10, pH 4-6 and pH 5-7 ampholines by Wallin's modification of the O'Farrell method. 22 HPLC of DTLIL3 on a TSK3000 column with PBS at 1 ml/min was performed along with protein standards BSA and ovalbumin. Optical density at 280 nm was monitored.
Reverse phase HPLC using a C4 Vydak column with a 0-70% acetonitrile in 0.05% trifluoroacetic acid mobile phase was performed with DTLIL3. Absorbance at 215 nm was measured. DTLIL3 (100 g) was ethanol precipitated and analyzed by Edmond degradation and HPLC. The sequence of the N-terminal 14 amino acids was determined.
Tryptic peptide mapping of DTLIL3 was performed by the method of Matsudaira.
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Tandem mass spectroscopy was performed on a Quattro II triple quadrupole mass spectrometer running MassLynx software after reverse phase HPLC as described above.
Cell lines
The hematopoietic growth factor-dependent human leukemia cell lines TF1, and the TF1 derivatives TF1/Bcl2, TF1⌬MEK+LNL6, TF1⌬MEK+Bcl2 were obtained from Dr J McCubrey and grown in RPMI 1640 medium with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate (GIBCO-BRL, Grand Island, NY, USA), 0.1 mM non-essential amino acids (GIBCO), 2 mM L-glutamine (GIBCO), 50 U/ml penicillin-G (GIBCO), 50 g/ml streptomycin sulfate (GIBCO), and 50 ng/ml human GM-CSF (Immunex, Seattle, WA, USA). OCI-AML and AML193 cells were obtained from the American Type Culture Collection (Rockville, MD, USA). Both cell lines were grown in Iscove's modified Dulbecco's medium with 25 mM Hepes and 10% FBS supplemented with 50 ng/ml GM-CSF. M07e cells were obtained from Dr D Hogge and grown in Dulbecco's MEM with 10% FBS, 10% 5637 conditioned medium, 50 M 2-mercaptoethanol, and 5 ng/ml human IL-3. HL60, K562, and CEM human leukemia cells, P815 murine mastocytoma, and TK6 human lymphoblastoid lines were obtained from the American Type Culture Collection and maintained on RPMI 1640 medium plus glutamine with 10% FBS and penicillin/streptomycin. The properties of the cell lines and their sources are described in Table 1 .
Cell line sensitivity to DTLIL3 molecule
For thymidine incorporation inhibition assays, 5 × 10 4 cells were incubated in 100 l RPMI 1640/15% FBS/ penicillin/streptomycin/glutamine in Costar 96-well flat-bot- 50 s were the concentrations of toxin which inhibited thymidine incorporation by 50% compared to control wells.
To evaluate inhibition of colony formation as another measure of cell kill, 2 × 10 4 AML cell lines were incubated with different concentrations of DTLIL3 (0-400 nM) in 150 l of RPMI 1640 medium plus 15% FBS supplemented with 50 ng/ml G-CSF (Amgen, Thousand Oaks, CA, USA) in 96-well flat-bottomed Costar plates. After 48 h, 50 and 100 l samples from each well were mixed with 1 ml methylcellulose medium (Methocult H4434, StemCell Technologies, Vancouver, BC, Canada) containing FBS, stem cell factor, GM-CSF, IL-3 and erythropoietin and poured into 35-mm gridded petri dishes (Nunc, Naperville, IL, USA). Dishes were placed in humidified chambers at 37°C/5% CO 2 for 14 days, after which colonies containing greater than 20 cells were counted. Both the concentrations of toxin reducing colony formation by 50% (IC 50 ) and the maximal log cell kill compared with controls were calculated as previously described. 4 For assays of apoptosis induction, aliquots of 1 × 10 6 cells were incubated in 24-well Costar plates at 37°C/5% CO 2 for 48 h in media with different concentrations of DTLIL3. Cells were then washed in PBS and resuspended in 100 l staining solution (containing Annexin-V fluorescein and propidium iodide in HEPES buffer, Annexin-V-FLOUS Staining Kit; Boerhinger-Mannheim). Following incubation at room temperature for 15 min, cells were analyzed by flow cytometry as previously described. 24 Cells were also examined by phase contrast microscopy to assess morphologic changes of apoptosis (nuclear condensation and fragmentation and cytosolic membrane blebbing). In selected experiments, apoptotic induction of internucleosomal fragmentation of genomic DNA was determined. 1 × 10 7 cells (4 × 10 5 /ml) were grown in the indicated conditions for 1 day. The cells were pelleted by centrifugation, resuspended in 500 l of lysis buffer (20 mM TrisHCl, pH 7.4, 10 mM EDTA, 0.2% Triton X-100) and placed on ice for 10 min. The lysate was then centrifuged for 10 min at 16 000 g, and the pellet discarded. Twenty l of 4 mg/ml protease K (Sigma) was added to the supernatant and the mixture was incubated overnight at room temperature. The solution was phenol extracted twice followed by chloroform extraction once. The aqueous phase was saved each time. The nucleic acids were ethanol precipitated and subsequently resuspended in water. The concentration of the nucleic acids was determined and 40 g was treated with 10 l of 0.25 mg/ml RNase A (Sigma) for 5-10 min. The remaining DNA was electrophoresed in an agarose gel with 1 × TBE (0.09 Tris borate, 0.002 M EDTA) running buffer and visualized with ethidium bromide.
In other experiments, cells were treated in 24-well Costar plates with 50 nM DTLIL3 for 0, 6, 12, 24, 48 and 60 h periods. Cell samples were reacted with 6 g/ml Hoeschst 33342 (Aldrich, Milwaukee, WI, USA) and apoptotic cells quantified using fluorescence microscopy. A total of at least 200 cells were counted, and the data calculated as percent apoptotic cells.
Acute phase CML, AML and normal marrow cells
With the approval of the respective Institutional Review Boards and after obtaining informed patient or parental consent, heparinized blood samples were obtained from 20 patients with myeloid acute phase CML and 17 patients with AML. Heparinized marrow aspirates were also obtained from five allogeneic bone marrow donors. Blood and marrow cells were diluted 1:1 with RPMI 1640 medium and layered over 0.3 vol of Ficoll-Hypaque (1.070 g/ml; Pharmacia, Piscataway, NJ, USA). After density gradient centrifugation at 1000 g for 30 min, light density cells (Ͻ1.077 g/ml) were diluted three-fold with RPMI 1640 and centrifuged again at 1300 r.p.m. for 10 min. Cells were then usually cryopreserved in 50% FBS with 10% dimethylsulfoxide. Upon thawing, cells were suspended in RPMI 1640 medium with 15% FBS and 2 mM L-glutamine, 50 U/ml penicillin G, 50 g/ml streptomycin sulfate with 1 mg/ml DNAse I (Sigma Chemicals). The DNAse reduces cell clumping with DNA released from necrotic cells.
Leukemic and normal progenitor cell sensitivity
To evaluate inhibition of colony formation, aliquots of 1 or 2 × 10 5 acute phase CML, AML and normal marrow light density cells were incubated with different concentrations of DTLIL3 (0-400 nM) in 150 l of RPMI 1640 medium plus 15% FBS supplemented with 50 ng/ml G-CSF (Amgen) in 96-well flat-bottomed Costar plates at 37°C/5% CO 2 in air. After 48 h, 50 and 100 l aliquots were plated in Methocult as described above for cell lines. Colonies were counted at 14-21 days.
Results
We designed an IL3R-directed fusion toxin for potential therapy of acute phase CML and AML. Our choice was based on the presence of IL3R on leukemic progenitors [10] [11] [12] [13] and on the biological potency for murine leukemic cells for similar diphtheria fusion molecules with murine IL3. 25, 26 Because of concern that steric hindrance from the diphtheria toxin might reduce the binding of the IL3 moiety to its receptor as was reported with murine IL3, 26 we synthesized a linker form of diphtheria IL3 fusion protein. The construct consisted of the first 388 amino acids of diphtheria toxin including both the catalytic and translocation domains fused via a His-Met-(Gly 4 Ser) 2 -linker to human IL3. The bacterial expression plasmid was successfully prepared and sequence confirmed and the construct is shown in Figure 1 .
Preparation of recombinant diphtheria IL3 toxin
Three liter fermentations were done using BR(DE3) E. coli transformed with pRKDTLIL3 DNA. The inclusion body yield for DTLIL3 was 79 mg protein. The refolded protein (pI of 6) was dialyzed against a low salt pH 7.4 buffer and bound to an anion exchange matrix (HiTrap Q) and eluted with a higher salt buffer (0.13 M NaCl once and 0.5 M NaCl for the concentrating chromatography step. Approximately 1.5 mg of recombinant protein was recovered from the columns from the starting 79 mg protein for a yield of 2%. All the bioactive, properly folded protein was in this fraction. Unbound and lower salt elution material (0-0.05 M NaCl) was not biologically active.
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Figure 1
Construction of pRKDTLIL3 bacterial expression plasmid. The BBG14 plasmid is a pUC18 plasmid with synthetic IL3 cDNA cloned between the HindIII and EcoRI sites in the polylinker. A PCR reaction was performed with the 5Ј-oligonucleotide: 5Ј-GCAGTCGACCATATGGGCGGAGGCGGAAGTGGAGGAGGAGGC AGCGCTCCCATGACCCAGACA-3Ј and the 3Ј-oligonucleotide: 5Ј-GCAGTCGCAAAGCTTCTAAAAGATCGCTAGCGACAA-3Ј. The PCR product was subcloned in the pCR-TOPO vector, restricted with NdeI and HindIII and ligated to the Ndel-HindIII restricted, alkaline phosphatase treated pRKDTGM 3.7 kb DNA fragment. Ligated DNA transformants were used to make plasmid preparations and these were sequenced and the pRKDTLIL3 plasmids isolated.
Similarly, higher salt elution protein was not biologically active and consisted of DT fragments (30-40 kDa Mr) with a pI of 5. A S200 column was then run in PBS at 0.5 ml/min. Monomeric DTLIL3 was recovered (0.45 mg/3) separate from approximately equal amounts of dimer and aggregate. Again, all the bioactivity was in the monomeric peak. Thus, the final yield of Ͼ80% pure DTLIL3 was 0.6% of the starting denatured protein. Endotoxin levels were minimized by extensive Triton X-100 washes of the inclusion bodies and by separating on anion exchange and size exclusion chromatographic matrices.
Characterization of DTLIL3
Reducing SDS-PAGE showed that the recombinant molecule was Ͼ80% pure. The recombinant protein had an apparent molecular weight of 58 kDa (Figure 2a) . Immunoblots with anti-DTA and anti-huIL3 revealed reactivity of a major protein species of the anticipated molecular weight (Figure 2b and c) . There are minor species of 50-55 kDa which react with anti-DTA but not anti-huIL3. They constitute between 10 and 20% of the product. ADP-ribosylating activity was found in DTLIL3. Compared to the enzymatic activity of CRM107 (a form of diphtheria toxin with the single point mutation S525F in the receptor binding domain and a fully active enzymatic domain), DTLIL3 was equally active. DTLIL3 lacked free thiols based on reaction with Ellman's reagent. The control ricin toxin A chain had the expected two free thiols/molecule (one internal and one external) and the diphtheria fusion molecule had р0.24 free thiols/molecule. Two-dimensional SDS-PAGE with isoelectric focusing revealed an approximately 58 kDa protein with a pI of 6 and Ͼ80% purity by densitometry. HPLC of DTLIL3 on a TSK3000 column with PBS revealed a single dominant peak with a retention time of 7.7 min whereas BSA (67 kDa) and ovalbumin (43 kDa) gave retention times of 7.5 and 8.3 min, respectively. This data was consistent with the predicted MW of DTLIL3 of 58 kDa. Reverse phase HPLC was performed using a C4 Vydak column with a 0-70% acetonitrile in 0.05% trifluoroacetic acid mobile phase. A single peak was observed at 49.4 min (49.5 min for DTGM). DTLIL3 (100 g) was ethanol precipitated and analyzed by Edmond degradation and HPLC (run No. 258, Wake Forest Protein Analysis Core Lab). The N-terminal 14 amino acids of DTLIL3 matched those of DT and DTGM. Tryptic peptide mapping of DTLIL3 showed a unique peptide pattern, different than DTGM. Tandem mass spectroscopy was performed on a Quattro II triple quadrupole mass spectrometer running MassLynx software and revealed a determined MW of 58 320 daltons vs a calculated MW for DTLIL3 based on complete DNA sequencing of the plasmid and intact disulfide bonds of 58 321 daltons.
Cytotoxicity of DTLIL3 to leukemic cell lines
Toxicity of DTLIL3 for leukemic cell lines was assessed by measuring inhibition of cell proliferation using 3 H-thymidine incorporation. The IC 50 was calculated as the concentration of fusion protein inhibiting thymidine incorporation by 50% compared to control. Representative cell cytotoxicity curves with 24 h incubations in DTLIL3 are shown in Figure 3 . A panel of 12 cell lines was incubated for 48 h with the fusion toxin and the results are described in Table 2 . Receptor positive cell lines were sensitive to drug with IC 50 s of 1-28 pM whereas proliferation of the receptor negative cell lines was not impaired at concentrations exceeding 1400 pM. The low receptor density HL60 cell line showed intermediate sensitivity (IC 50 = 119 pM). Co-incubation with human IL3 (1500 ng/ml) blocked toxicity to TF1/Bcl2 cells by 120-fold ( Figure 4) . The IC 50 for TF1/Bcl2 without blocking IL3 was 1 pM and with IL3 was 162 pM.
Inhibition of colony formation by DTLIL3 for the TF1/Bcl2 IL3 receptor positive cell line and the CEM IL3 receptor negative cell line was measured. The results are shown in Figure  5 . The IC 50 for TF1/Bcl2 cells was 14 pM and at 1000 pM over 3 logs cell kill was observed. This is the maximal log cell kill detectable with this assay. In contrast, no inhibition of colony formation by CEM cells was seen even when incubated with 20 000 pM DTLIL3.
AML193 cells were incubated with 2 ng/ml IL3 and with or without 624 pMDTLIL3 for 1, 2, 3 or 4 days and apoptosis measured by morphology under phase contrast microscopy and flow cytometry after staining with annexin V-FITC and propidium iodide. Apoptosis measured by flow cytometry in the absence of fusion toxin was 10% for each day, while apoptosis in the presence of toxin rose to 30% on day 1, 31% on day 2, 40% on day 3 and 60% on day 4. Morphologic changes and nuclear DNA fragmentation associated with apoptosis were clearly demonstrated after 48 h in the presence of fusion protein ( Figure 6 ). The experiment was performed twice.
TF1 cells incubated with 50 ng/ml human GM-CSF and 5 nM DTLIL3 for 0, 6, 12, 24, 48 and 60 h and evaluated for apoptotic nuclear bodies by Hoeschst staining showed 11%, 10%, 10%, 12%, 31%, 47%, and 68% apoptosis, respectively. Control TF1 cells showed 10% apoptosis over the same time period.
Leukemic progenitor sensitivity
Colony growth was observed under our semi-solid culture conditions for 11/20 myeloid acute phase CML samples and 9/17 AML samples. For 4/11 myeloid acute phase CML patient
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Figure 5
DTLIL3 inhibition of colony formation in semi-solid medium. Cells were exposed to fusion protein at different concentrations for 48 h and then aliquoted in 0.3% agarose. Colonies with Ͼ20 cells counted on day 7. () CEM; (᭹) TF1/Bcl2. progenitor cell samples, there was у1 log cell kill at 680 pM with IC 50 s of 7-27 pM ( Figure 7 and Table 3) , and 3/9 AML patient progenitor cell samples had у1 log cell kill at 680 pM with IC 50 s of 3-68 pM. Because colony growth on many samples was limited to 10-200 colonies/10 5 cells, the maximal log cell kill may be an underestimate. This assay detected only the reduction in colony growth seen in 35 mm dishes so that the range varied from 1 to 3 logs.
Normal progenitor sensitivity
Five normal marrow light density mononuclear cell preparations were incubated with DTLIL3 for 48 h and then assayed for CFU-GM. The IC 50 was 81-675 pM with 0.5 log cell kill at 680 pM ( Figure 7 and Table 3 ).
Discussion
Drug-resistant myeloid blasts frequently show overexpression of membrane-dependent drug transporters (P-glycoprotein and lung resistance protein) 27, 28 and drug metabolizing enzymes (glutathione S-transferase ).
29 Fusion toxins bypass these drug resistance pathways due to their distinct molecular shape and mechanism of action. We have previously demonstrated the cytotoxic potency of the DTGM fusion toxin both for multi-drug resistant cell lines and fresh patient leukemic progenitors.
4,5 DTLIL3 may be particularly useful in acute phase CML where the majority of patients present with disease refractory to cytotoxic drugs that target cell proliferation or DNA.
The yield of DTLIL3 was low and reflects the lack of optimization of refolding. Nevertheless, the purity of final product, Ͼ80%, suggests the purification method is good. The contaminant appears to be proteolytically cleaved DTLIL3 with smaller 45 kDa Mr material that is immunoreactive with anti-DTA but not anti-IL3. Use of newer expression vectors and use of affinity tags may yield improved yields and purity. In fact, preliminary results with a pET21 construct have given three-fold higher yields and Ͼ90% purity after Ni 2+ affinity chromatography (unpublished results). We have generated adequate quantities (2.5 mg) of DTLIL3 for further in vitro and in vivo testing.
Diphtheria fusion protein directed to the mouse IL3R has been developed by two laboratories. 25, 26 In both cases, selective toxicity to receptor positive murine leukemic blasts was seen. Less damage to normal murine progenitors was observed, and adoptive transfer experiments indicated the absence of IL3 receptors on at least a subset of repopulating progenitor cells. 25 Our study with a diphtheria fusion protein targeting the human IL3R has given similar results so far in the ex vivo targeting of human IL3R-bearing cells.
DTLIL3 cytotoxicity was mediated by IL3R binding based both on blocking with human IL3 and selective toxicity to IL3R-positive leukemic cell lines. Toxicity was measured by inhibition of cell proliferation, dye exclusion, colony formation and by the induction of apoptosis. The delay in apoptosis to 48-60 h corresponds with the time required for toxin internalization, translocation and EF2 inactivation. 30 Mutation of the p53 gene and loss of its function is frequently observed in acute phase CML. 31 Mutant p53 cells have poor apoptosis induction by conventional cytotoxic drugs. 32 In our study, p53-deficient cell lines (including TF1) 33 were readily killed by DTLIL3 suggesting the fusion toxin bypasses this mechanism of drug resistance. Toxicity of DTLIL3 to fresh leukemic progenitors as well as cell lines is encouraging, since some targeted toxins have been much less effective on patient samples than cell lines. 34, 35 However, a number of our patient samples were relatively resistant to DTLIL3 suggesting that expression of the IL-3R on leukemic progenitors is variable. It is interesting to hypothesize that the sensitivity of some patient samples to the toxin may reflect the presence of an IL3-IL3R autocrine loop in these cells as has been previously described. 13 The reduced but measurable sensitivity of CFU-GM to DTLIL3 suggests the resistance of CFU-GM to DTGM is not a general resistance to diphtheria toxin-mediated cell damage. Specific attributes such as altered GM-CSF receptor physiology on normal vs malignant cells may account for the DTGM selectivity. 36 Since earlier normal myeloid progenitors (LTC-IC) are less likely to require IL3 and express IL3 recep- tors, they may show greater resistance to DTLIL3. 9 We are currently evaluating this hypothesis.
An in vitro therapeutic index reported by Ghielmini and others, can be calculated by comparison of the IC 50 of DTLIL3 on sensitive leukemic CFC with that of normal CFU-GM. [37] [38] [39] In these studies, we observed an in vitro index of 4-12, where values greater than 1 would suggest selective toxicity towards malignant progenitors. In comparison, when conventional chemotherapeutic agents including doxorubicin, melphalan and cytarabine have been tested in similar assays, 37-39 the indices obtained were Ͻ5. It will be interesting to observe whether or not the relative toxicity of DTLIL3 against normal and leukemic targets will be similar when more primitive progenitors that can be detected in long-term stromal co-cultures or immunudeficient mice are studied.
DTLIL3 may also target non-hematopoietic tissues possessing high affinity IL3R. [40] [41] [42] In vivo toxicology studies in animals with cross-reactive receptors will be necessary to address potential non-hematopoietic toxicities.
Synergy with cytotoxic chemotherapy is likely to be observed with DTLIL3 as has been documented with DTGM. 24, 43 Preliminary results suggest similar DTLIL3 synergy with cytarabine as was seen with DTGM (Frankel, unpublished observations) . Applications of such biologicals with conventional chemotherapy should permit reductions in dose and toxicities of each agent and improved efficacy for the combination.
DTLIL3 may be a clinically useful reagent. The related diphtheria fusion protein, DAB 389 IL2, has completed a phase II Leukemia trial with 73 refractory cutaneous T cell lymphoma patients. 44 At 9 and 18 g/kg/day given by intravenous infusion over 15 min for 5 days for two to eight courses, 10% of patients had complete remissions and 20% of patients had partial remissions lasting 3-12+ months. The AML fusion toxin, DTGM, is currently in a phase I dose escalation study. Fourteen relapsed AML patients have been treated at 1, 2, 3, or 4 g/kg/day for 5 days by 15 min intravenous infusion with side-effects limited to rare fever, transaminasemia and hypotension ameliorated by steroid prophylaxis. Thus, there is a growing clinical experience in leukemia and lymphoma patients with related molecules. DTLIL3 has the advantage of minimal IL3R expression on monocytes/macrophages. In the absence of effective strategies for the treatment of acute phase CML and patients with refractory AML, the experiments in this study suggest the need for further preclinical development of DTLIL3 as a possible new therapeutic agent for this group of poor prognosis patients. DTLIL3 may be used clinically either as a purging agent for autologous stem cell or bone marrow transplants or for systemic treatment of chemotherapyresistant AML or blast crisis CML.
